Insurers Deny Targeted Rare Cancer Treatments Despite Genomic Evidence

By Arthur Allen · KFF Health News · 2026-09-22

Insurers Deny Targeted Rare Cancer Treatments Despite Genomic Evidence

According to KFF Health News, patients with rare tumors face significant financial barriers when seeking precision therapies that lack specific FDA approval for their conditions. The report highlights how pharmacy benefit managers often reject claims for expensive drugs like Lynp

According to KFF Health News, patients with rare tumors face significant financial barriers when seeking precision therapies that lack specific FDA approval for their conditions. The report highlights how pharmacy benefit managers often reject claims for expensive drugs like Lynp